Skip to content

NewAmsterdam Pharma

US · NAMS #2583 by market cap Listed 1970
18.41 -1.10 -5.64%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 8 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.2 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
108.68% +1.21pp
Institutions
251 -8
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund46.40%
VC/PE Fund36.41%
Hedge Fund17.10%
Public Company3.39%
Family Office/Trust2.57%
Private Company1.98%
Individual/Insider0.88%
Sovereign Wealth Fund0.70%
Government Pension Fund0.12%

Top holders as of 2026-09-18

Frazier Life Sciences Management, LP 15.79% · 18.94M sh
Capital Research 12.28% · 14.72M sh
FMR 10.10% · 12.12M sh
RA Capital Management, L.P. 7.96% · 9.55M sh
Forbion Capital Partners B.V. 7.08% · 8.49M sh
Deerfield Management Company, L.P. 3.56% · 4.26M sh
Viking Global Investors LP 3.51% · 4.20M sh
Bain Capital Life Sciences Investors, LLC 3.17% · 3.81M sh
Maverick Capital, Ltd. 2.72% · 3.27M sh
Duquesne Family Office LLC 2.56% · 3.07M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 26 sells

NameRoleStake
Frazier Life Sciences Management, LP -- 15.79%
Michael Davidson Chief Executive Officer 0.76%
Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director 0.06%
Hilde van der Kamp Independent Non-Executive Director 0.03%
Douglas Kling Former Chief Operating Officer 0.01%
Mayur Somaiya Chief Financial Officer 0.01%
Adele M. Gulfo Independent Director 0.00%
Louise Kooij Former Chief Accounting Officer 0.00%
Louis Lange Independent Non-Executive Director 0.00%
William Lewis Independent Chairman of Board of Directors 0.00%
Mark McKenna Independent Non-Executive Vice Chairman 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-29 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Derivative Exercise and Sale -50,246 $25.03
2026-09-13 Michael Davidson Chief Executive Officer Open Market Acquisition +10,000 $22.65
2026-09-03 John Smither Independent Director Open Market Disposition -1,600 $25.32
2026-08-31 Robert Gunning Principal Accounting Officer, VP & Controller Other Acquisition +3,200 --
2026-08-31 Robert Gunning Principal Accounting Officer, VP & Controller Other Derivative Acquisition +14,000 $24.92
2026-08-24 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Intent to Sell (Form 144) -250,000 --
2026-08-23 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Derivative Exercise and Sale -125,000 $26.91
2026-07-19 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -105,000 $11.17–31.71
2026-06-21 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -40,000 $10.90–30.73
2026-05-25 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -65,000 $10.00–35.69
2026-03-10 Louis Lange Independent Non-Executive Director Open Market Disposition -44,619 $30.41–31.23
2026-03-08 Louis Lange Independent Non-Executive Director Derivative Exercise and Retained +44,619 $11.50
2026-03-08 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Derivative Exercise and Sale -300,000 $30.29–30.32
2026-03-05 Louis Lange Independent Non-Executive Director Open Market Disposition -28,186 $29.41
2026-03-01 Michael Davidson Chief Executive Officer Derivative Exercise and Sale -443,707 $33.25
2026-03-01 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Intent to Sell (Form 144) -300,000 $31.18
2026-02-25 Michael Davidson Chief Executive Officer Derivative Exercise and Sale -306,293 $33.63–36.68
2026-02-23 Michael Davidson Chief Executive Officer Intent to Sell (Form 144) -750,000 $36.17
2026-02-19 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Open Market Disposition -45,481 $35.00–35.46
2026-01-27 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -72,428 $10.90–32.62

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

NewAmsterdam Pharma discussion 0 comments

Add a comment